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Abstract: Nanoparticles have an enormous potential for development in biomedical applications, 
such as gene or drug delivery. We developed and characterized aminopropyltriethoxysilane-
functionalized silicon dioxide nanoparticles (APTES-SiNPs) for gene therapy. Lipofectamine® 
2000, a commonly used agent, served as a contrast. We showed that APTES-SiNPs had a gene 
transfection efficiency almost equal to that of Lipofectamine 2000, but with lower cytotoxicity. 
Thus, these novel APTES-SiNPs can achieve highly efficient transfection of plasmid DNA, 
and to some extent reduce cytotoxicity, which might overcome the critical drawbacks in vivo 
of conventional carriers, such as viral vectors, organic polymers, and liposomes, and seem to 
be a promising nonviral gene therapy vector.
Keywords: aminopropyltriethoxysilane, silicon dioxide nanoparticles, Lipofectamine® 2000, 
gene therapy vector, nanomedicine
Introduction
Nanomedicine is an emerging new field created by fusion of nanotechnology and 
medicine in a straightforward manner by adding, correcting, or replacing genes. A key 
problem in gene therapy is the efficient delivery of genetic material to target cells in a 
patient without significant toxicity and side effects. A number of novel delivery strategies 
have been proposed to enhance the efficiency of plasmid DNA (pDNA) transfection. 
Nevertheless, the reliability of the carrier is still a critical concern for any gene therapy. 
An ideal gene delivery system should be biodegradable, nontoxic, nonimmunogenic, 
stable, and target-specific, should assist to improve gene expression, and be able to be 
used to treat genetic diseases which require systemic administration of therapy.
Nanoscale gene carriers traditionally include viral vectors, organic polymers, and 
liposomes.1,2 Viral vectors have been used widely for effective DNA delivery, but their 
potential immune response, difficult recombination, and high cost have hampered their 
applications.3 Nonviral polymer carriers have more potential for gene and drug delivery 
because of such advantages as easy preparation and reduced risk of immune response. 
Cationic polymers and liposomes have recently shown promise,4,5 and solid lipid nano-
particles have also been shown to be a useful vehicle for gene therapy.6 However, any 
benefits due to their cationic nature are offset by their instability in serum and high 
cytotoxicity profile. A number of approaches have been attempted to overcome the 
cytotoxicity limitation and to make nonviral cationic systems safer.7 An ideal method 
with both high transfection efficiency and relative safety in vitro and in vivo has not 
been found, so more attention needs to be devoted to finding new materials.
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Fortunately, inorganic nanoparticles such as those made 
from hydroxyapatite and silicon, offer promise as gene and 
drug transfer carriers because of their biocompatibility, lack 
of toxicity, and stable physical and chemical properties.8 
Silicon nanoparticles have been used recently as gene carriers 
in the transfection of pDNA.9
Furthermore, enormous effort has been devoted to surface 
modification of various polymer drug vectors in order to 
improve their biocompatibility, resist protein adsorption, and 
increase their circulation time and internalization efficiency.10 
Common functionalization procedures for preparing surfaces 
for protein binding utilize silane compounds with terminal 
functional groups that interact electrostatically or covalently 
with protein surface groups to increase protein adsorption. 
One common chemical used for surface functionalization is 
aminopropyltriethoxysilane (APTES), which has the chemical 
formula NH2 (CH2)3–Si(OC2H5)3.11–14 The silane end of the 
APTES molecule binds covalently to surface silicon atoms, and 
the amino end of the molecule increases protein adsorption on 
the surface by electrostatic interactions. The structural transition 
of a single dsDNA molecule immobilized on an APTES-treated 
substrate has been demonstrated. DNA binding to the APTES 
linker is much stronger than that on an alkylthiol/substrate.15 
Also, APTES can dissolve in both polar and nonpolar solvents, 
and also has high solubility in cell membranes.16,17
Here we report a pDNA carrier based on APTES-
  modified silica nanoparticles (APTES-SiNPs), the surface of 
which was functionalized with TX-100 in order to enhance its 
monodispersity. It was produced by a guided self-assembly 
approach to the manufacture of DNA nanostructures on a 
silicon substrate. Because of the unique profiles of APTES 
and the silica nanoparticles, the novel APTES-SiNP vector 
has a large surface area to volume ratio, tends to agglomerate, 
and absorbs more pDNA.
In order to evaluate the transfection efficiency and safety 
of APTES-SiNPs, we investigated the ability of these novel 
nanoparticles to condense the plasmid encoding for enhanced 
green fluorescent protein (pEGFP) and transfer it into 
human vascular smooth muscle cells (HVSMCs). Using this 
approach, we compared the stability, plasmid immobilization, 
transfection efficiency, and cytotoxicity of this formulation 
with widely used conventional Lipofectamine® 2000 in order 
to evaluate its potential as a gene transfection vector.
Materials and methods
Materials
All chemicals, ie, APTES (Alfa Aesar, Ward Hill, MA), 
methyltrimethoxysilane (Alfa Aesar), and Triton X-100 
(Sigma-Aldrich, St Louis, MO) were used without further 
purification. All the glassware (glass bottle and small pieces 
of glass substrate) was cleaned and sonicated in ethanol for 
5 minutes, rinsed with double distilled water, soaked in a 
H2O/HNO3 (65%)/H2O2 (1:1:1, v/v/v) solution, rinsed again 
with doubly distilled water, and finally dried in air.
Synthesis of ATPES-SiNPs
APTES 0.1 mL and TX-100 0.3 mL were dissolved in 20 mL 
of double distilled water and stirred for 10 minutes. Methyl-
trimethoxysilane 2 mL was added, followed by stirring for 
10 minutes, with subsequent addition of 28% NH3H2O to 
reach a pH of 11. The solution was stirred for 5 hours, then 
left overnight at room temperature. Finally, the product was 
collected by centrifugation, rinsed with double distilled water 
and ethanol, and allowed to dry at room temperature.
Agarose gel electrophoresis
Complex formation between the nanoparticles and pDNA 
was analyzed by 1% agarose gel electrophoresis. The 
pDNA-APTES complex was prepared according to the fol-
lowing process. Briefly, 1 µL of APTES-SiNP in solution 
(5 mg/500 µL in water) was added to 1 µL of pDNA aqueous 
solution (0.1 µg/µL) and 8 µL water (pH 7.4) in a microcen-
trifuge tube. The resulting pDNA/APTES-SiNP complexes 
were left at room temperature for 30 minutes to facilitate 
complexation. The samples were centrifuged at 5000 rpm 
for 5 minutes, after which the suspension was obtained and 
analyzed by loading onto 1% agarose gel with ethidium 
bromide (0.1 µg/mL) and running with Tris-acetate buffer 
at 100 V for 30 minutes. DNA retardation was observed by 
irradiation with ultraviolet light.
Transfection of cultured cells
HVSMCs were cultured in 75 cm2 flasks in Dulbecco’s 
  modified Eagle’s medium (Gibco BRL, Carlsbad, CA) 
  supplemented with 10% fetal bovine serum, 50 Ag/mL 
  penicillin, 50 Ag/mL streptomycin, and 100 Ag/mL neomycin 
at 37°C in a humidified 5% CO2-containing atmosphere. For 
the transfection experiments, the cells were trypsinized and 
seeded into a 6-well plate at a density of 2.5 × 105 cells/well 
overnight before the transfection procedure was   performed. 
The cells were washed with phosphate-buffered solution 
twice prior to the addition of Optimen® 2 mL. The transfec-
tion procedure consisted of 12 µL pEGFP (185 µg/mL) with 
12 µL APTES-SiNP solution (APTES-SiNPs 5 mg/Tris-
EDTA 500 µL), and 18 µL water (pH 7.4) in one microcen-
trifuge tube. The contents were then mixed together gently 
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and incubated at room temperature for 30 minutes. The cells 
were then incubated at 37°C in 5% CO2. After 5 hours, the 
complexes were aspirated and replaced with culture medium. 
After 48 hours, the cells were assayed for green fluorescent 
protein expression, both qualitatively by fluorescence micros-
copy and quantitatively by fluorescence-activated cell sorting. 
The cells were washed twice with phosphate-buffered solu-
tion and collected by trypsinization, centrifuged at 2000 g 
for 2 minutes, and washed twice with phosphate-buffered 
solution. The cells were then resuspended in phosphate-
buffered solution and analyzed by flow cytometry (Beckman 
Coulter, Brea, CA).
Statistical analysis
All experimental measurements were collected in triplicate. 
The values are expressed as the mean ± standard deviation. 
The statistical significance of differences in cell viability 
was examined using one-way analysis of variance followed 
by Fisher’s least significant difference test. The significance 
level was set at P , 0.05.
Results and discussion
Nanoparticle size and zeta potential 
measurement
The nanoparticles were characterized by scanning electron 
microscopy and elemental analysis (x-ray photoelectron 
spectrometry, Figure 1). The mean size of the APTES-SiNPs 
was found to be 174.5 nm by dynamic light scattering.
Several approaches have been proposed to increase 
the surface area of the solid-phase support to enhance the 
capacity for DNA. Examples include the use of smaller-
sized particles. Decreasing the particle size has proved to 
be an effective method of increasing the surface area for 
DNA absorption.18 However, too small a particle size can 
cause extremely high back pressure during the extraction 
procedure. The monotonic decrease of the size of small 
particles to increase the surface area of the solid phase has 
consequently been limited in practical application. Nanoma-
terials with unique properties such as a large surface area, 
pore structure, embedded effect, and size effect have been 
used effectively in bioanalysis and drug delivery.19,20
After amino functionalization, zeta potential measure-
ments carried out using a Beckman Delsa Nano C at an 
APTES-SiNP concentration of 1 g/L at 20°C demonstrated 
that the APTES-SiNP particles had a positive surface poten-
tial of +41.8 mV. We assessed pDNA condensation and 
integrity using gel electrophoresis (Figure 2). The positive 
potential might have resulted from protonation of amino 
groups on the surface of APTES-SiNPs. Therefore, the 
positively charged silica nanoparticles could be obtained 
directly without further modification and could combine with 
the negatively charged pDNA as a carrier for DNA delivery. 
The positively charged silica APTES-SiNPs could combine 
with negatively charged pDNA by electrostatic interactions 
to form APTES-SiNP-pDNA complexes.
A suitable ratio of silicon to pDNA was about 30:1, 
indicating that the positive charge density of APTES-SiNPs 
is not very high, considering their large diameter. Generally 
speaking, a lower positive charge density would reduce 
cytotoxicity.
Gel electrophoresis analysis
Binding of APTES-SiNPs to polyanionic pDNA was studied 
using the electrophoretic mobility of pDNA in agarose gel. 
The complexes were formed in deionized water by mixing a 
fixed amount of pDNA with increasing amounts of APTES-
SiNPs in such a way as to obtain APTES-SiNPs:pDNA 
Figure 1 Scanning electron microscopic images of amino-modified silicon nanoparticles.
Note: Bars, 500 nm.
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weight ratios ranging from 50:1 to 1:1, corresponding to the 
w/w ratio indicated in Figure 2. The efficiency of pDNA com-
plexation with APTES-SiNPs after 30 minutes of incubation 
was evaluated by the amount of APTES-SiNPs required to 
retard migration of pDNA toward the cathode during agarose 
gel electrophoresis. Efficient complexation of pEGFP by 
APTES-SiNPs led to pDNA immobilization. As can be seen 
in Figure 2, at the higher two ratios of APTES-SiNPs:pDNA 
assayed, stable complexes were formed. The absence of DNA 
in lines 2 to 3 confirms that DNA was completely immobi-
lized inside the complexes.
In summary, APTES-SiNPs have size and zeta potential 
values similar to those of other carriers and the same capacity 
to complex pDNA. Two bands (Figure 2) were character-
ized for their capacity to condense pDNA and to transfect 
HVSMCs.
Cytotoxicity
Gene vectors should not induce cytotoxic effects in gene 
therapy,21 so the low cytotoxicity of APTES-SiNPs:pDNA 
is very important. Nonviral delivery systems have certain 
drawbacks, such as cytotoxic reactions, especially when 
cationic lipids are involved.22 Cationic formulations have 
been reported to affect cell proliferation, differentiation, 
and proapoptotic genes in human epithelial cells. The poly-
cationic nature of synthetic nonviral gene transfer systems 
induces cytotoxicity by necrosis and apoptosis.
Therefore, evaluation of the cytotoxicity of cationic gene 
delivery systems is essential. In the present study, the toxicity 
of APTES-SiNPs was compared with that of Lipofectamine 
2000 in HVSMCs by flow cytometry in vitro, as shown in 
Figure 3. We observed that Lipofectamine 2000 was much 
more toxic than APTES-SiNP to cells.
Previous studies have shown that mesoporous silica 
nanoparticles are nontoxic and biocompatible,23,24 sufficiently 
excreted via the renal route,25 and promising candidates 
for drug delivery applications.25,26 Our study results are in 
accordance with those of a previous study showing that 
APTES-SiNPs have almost no adverse effects on human 
cells. However, there is an increasing body of evidence sug-
gesting that the surface properties of nanoparticles can have 
considerable toxicity.27 The toxicity of cationic polymers has 
been reported to be a function of the interactions of the poly-
mers with cell membranes and/or the efficiency of cellular 
uptake.28,29 As show in Figure 3, APTES-SiNPs actually do 
have some adverse effects on human cells, mainly ascrib-
able to APTES. However, quaternized APTES derivatives 
show less cytotoxicity than regular APTES because they 
maintain a cationic charge inside the polymeric backbone 
shielded by surface hydroxyl groups. This could explain 
why the cytotoxicity of APTES is low after it is fixed onto 
silicon nanoparticles.
The higher cell viability observed for APTES-SiNPs is 
probably due to the better cell compatibility of the silicon 
particles. As a consequence, APTES-SiNPs maintain the 
same low level of cytotoxicity even at high particle concen-
trations and a long cell contact time.
DNA
50:1 30:1 20:1 10:1
qual ratio (silicon: DNA)
1:1 only
Figure  2  Agarose  gel  electrophoresis  assay  demonstrating  APTES-SiNP-DNA 
complexation. A  constant  amount  of  DNA  was  complexed  with  nanoparticles 
at different ratios of 50:1, 30:1, 20:1, 10:1, and 1:1 (10 mM, pH 7.4). No 50:1 or 
30:1 APTES-SiNP-DNA band is observed because of fluorescence quenching by 
nanoparticle complexation.
Abbreviations:  APTES,  aminopropyltriethoxysilane;  SiNP,  silicon  dioxide 
nanoparticle.
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Figure 3 Cell viability assay. Cytotoxicity of Lipofectamine® 2000 and APTES-SiNPs 
on human vascular smooth muscle cells. After 48 hours of incubation, cell viability 
was measured by flow cytometry. Silicon nanoparticles had negligible toxicity to 
human vascular smooth muscle cells compared with Lipofectamine 2000.
Notes: *P , 0.05 for APTES-SiNPs versus control;  §P , 0.05 for Lipofectamine 
2000 versus APTES-SiNPs.
Abbreviations:  APTES,  aminopropyltriethoxysilane;  SiNPs,  silicon  dioxide 
nanoparticles.
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Transfection
In the present study, we found that the nature of the chemical 
groups on the surface of APTES-SiNPs is a critical factor 
affecting transfection efficiency. We modified the surface of 
the silicon nanoparticles and evaluated the ability of the mica 
to deliver the pEGFP gene into HVSMCs. Our results show 
that the APTES-SiNPs were able to deliver pEGFP into cells 
(Figures 4 and 5). They also suggest that the positive charge 
introduced by an amino group might allow the APTES-
SiNPs to bind to anionic pDNA and the cell membrane via 
electrostatic interactions, which could be the initial step for 
gene transfection.
We have developed an optimal method to protect DNA 
from cleavage by using bioconjugated amino-modified 
silicon nanoparticles. Our results clearly show that DNA 
could be easily enriched onto the positively charged surface 
of the nanoparticles for further manipulation. The DNA 
strands are protected from enzymatic cleavage and have the 
same properties as free DNA strands when released from the 
nanoparticles. The plasmids released are biologically active. 
This bionanotechnology is simple and efficient for protecting 
DNA strands. It will be highly useful in DNA separation, 
purification, manipulation, and detection, and possibly in 
genetic engineering and gene therapy.
The DNA delivery pathway involves the following steps. 
First, nanoparticles are adsorbed onto the cell membrane. The 
nanoparticles are then taken up by cells via endocytosis.30,31 
Certain intracellular processes can avoid transport of DNA 
across the cell membrane into the nucleus. Endosomal deg-
radation of DNA can occur during endocytosis inside an 
endosome if DNA does not escape from the endosome before 
fusion with lysosomes (in which pH is ,5).32
In a previous study it was reported that hydrophilic 
APTES nanoparticles are actively taken up by tumor cells 
in vitro, as seen by fluorescence staining of the cytoplasm.33 
This cytoplasmic staining has been observed for a few types 
of tumor cells that we have investigated, an example of which 
is HVSMCs. Although the mechanism for this type of cellular 
uptake is not yet fully understood, the net negative charge on 
the nanoparticles is thought to play a crucial role. A similar 
observation was made in a recent study that demonstrated 
high specific uptake of anionic magnetic nanoparticles by 
cells in vitro.34 In gene delivery, the genetic material should 
migrate to the nucleus as soon as it is released inside the 
cytoplasm of a cell.35 Again, optical imaging can play a sig-
nificant role in studying this nuclear migration of DNA. In the 
present study, we irreversibly tagged DNA with fluorescent 
APTES-SiNPs and unlabeled silicon nanoparticle complexes, 
as described in the experimental program. The post-release 
nuclear trafficking of DNA is demonstrated in the confocal 
image of HVSMCs. After comparison of this image with 
the image of HVSMCs stained with amino-encapsulated 
nanoparticles, it can be seen that there is considerable stain-
ing inside the nucleus in addition to cytoplasmic staining 
(Figure 4). However, these amino-modified nanoparticles are 
not able to penetrate the cell nucleus. Thus, we believe that 
this nuclear staining is a result of migration of the labeled 
DNA released inside the nucleus. A recent study report on 
the mobility of DNA molecules inside cells indicates that free 
DNA molecules can move in the cytoplasm, and that a small 
portion of them can reach the intranuclear space.36
This nuclear accumulation of foreign DNA can be 
increased by tagging with nucleus-targeting peptides.37 
Finally, to confirm that the DNA delivered is functional, 
Figure 4 Human vascular smooth muscle cells transfected with pEGFP delivered with APTES-SiNPs. A combined transmission and fluorescence image is shown. Fluorescence 
spectra of pEGFP taken in human vascular smooth muscle cells (magnification 400×).
Abbreviations: APTES, aminopropyltriethoxysilane; SiNPs, silicon dioxide nanoparticles; pEGFP, plasmid encoding for enhanced green fluorescent protein.
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pEGFP expression was checked by transfection of cultured 
cells. We observed that pEGFP was transfected successfully 
using APTES-SiNPs as the delivery vector. The observed 
green cellular fluorescence was from the expressed pEGFP, 
which was confirmed by localized spectroscopy (Figure 4). 
Our investigation shows that the nanomedicine approach 
using APTES-SiNPs is a promising direction for nonviral 
gene delivery.
Conclusion
In recent years, the transfection effect of nonviral carriers 
has been emphasized whilst overlooking the critical issue of 
cytotoxicity. Consequently, even though we have found many 
highly promising efficient carriers in vitro, their potential 
immune response, difficult recombination, and high cost has 
hampered their application in vivo.3 Undoubtedly, the basic 
requirement of a new carrier is transfection efficiency, but its 
safety is likely to play a pivotal role in its clinical application. 
We need to devote more attention to modification of the struc-
tural aspects of these carriers to minimize their toxicity and 
also find new materials, such as silicon nanoparticles, because 
transfection efficiency can be easily improved by increasing 
the weight ratio, whereas toxicity cannot be tackled so easily. 
Most new carriers found in recent years have been discarded 
upon practical application, for similar reasons.
In the present study, positively charged APTES-SiNPs 
with an average diameter of 174.5 nm were synthesized as 
pDNA carriers using a water-in-oil microemulsion method. 
The positively charged APTES-SiNPs were able to combine 
with the negatively charged pDNA by electrostatic interac-
tions to form a bioconjugate favorable for cellular uptake. 
The APTES-SiNPs were able to protect the pDNA in the 
complex from nuclease degradation. In vitro investigation 
suggested that the APTES-SiNP carriers could efficiently 
transfect pEGFP into HVSMCs, although the gene trans-
fection efficiency was a little lower than that achieved by 
the more widely used Lipofectamine 2000 (Figure 5). It is 
worthwhile to emphasize that the toxicity of the APTES-SiNP 
carriers was lower than that of Lipofectamine 2000, and that 
they showed good biocompatibility and almost no cytotoxic-
ity to HVSMCs. Further, the surface of APTES-SiNPs can 
also be chemically modified with various functional groups, 
such as cancer-specific antibodies or ligands, for targeting 
purposes.38–42 Considering all of the data, APTES-SiNPs may 
be superior to Lipofectamine 2000 as carriers of pDNA in 
HVSMCs, and may be a promising nonviral gene therapy 
vector.
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